Preserving fertility after chemotherapy is an important issue for many, many younger women diagnosed with early-stage breast cancer. Dr. Matteo Lambertini, medical oncologist at the Institute Jules Bordet Brussels, presented research at the 2017 San Antonio Breast Cancer Symposium showing that ovarian suppression with a gonadotropin-releasing hormone analogue such as Lupron, Trelstar, or Zoladex, can safely protect ovarian function and may help preserve fertility in younger women being treated with chemotherapy for early-stage disease. Listen to the podcast to hear Dr. Lambertini explain: why earlier studies on this topic had mixed results the results of the study the side effects of gonadotropin-releasing hormone analogues the strategies he recommends to his younger patients diagnosed with early-stage breast cancer who want to have a child after chemotherapy

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related